диссертации / 81
.pdf241
286.Nishimoto N., Terao K., Mima T. et al. et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease // Blood. - 2008. – Vol. 112. – P. 3959-3964.
287.Garnero P., Thompson E., Woodworth T. et al. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone // Arthritis Rheum. – 2010. – Vol. 62(1). – P. 33-43.
288.Олюнин Ю. А. Оценка статуса больных ревматоидным артритом // Науч-практич. ревматология. – 2012. - № 50(1). – С. 9-13.
289.О.А. Кричевская, Д.В. Горячев, А.В. Смирнов, Ш.Ф. Эрдес. Некоторые методы оценки прогрессирования рентгенологических проявлений ревматоидного артрит // Научн-практич. ревматология. – 2007. -
№2. – С. 56-63.
290.van der Heijde D.M. How to read radiographs according to the Sharp/van der Heijde method // J. Rheumatol. – 1999. – Vol. 26(3). – P. 743-745.
291.Смирнов А.В. Дифференциальная рентгенологическая диагностика поражения суставов кисти при ревматических заболеваниях // Consilium medicum. - 2005. - № 2. - 76-83.
292.Arnett F.C., Edworthy S.M., Bloch D.A. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis // Arthr. Rheum. – 1988. – Vol. 31. – P. 315-324.
293.Насонов Е.Л. Применение инфликсимаба (моноклональные антитела к фактору некроза опухоли) в ревматологии: новые данные // РМЖ. – 2004. -
№20. – С. 1123–1127.
242
294. Reff M.E., Carner K., Chambers K.S. et al. Depletion of B cells in vivo by a chimeric mouse human antibody to CD20 // Blood. – 1994. – Vol. 83. – P. 435– 445.
295.Sato K., Tsuchiya M., Saldanha J. et al.Reshaping a human antibody to inhibit the inerieukin-6-dependent tumor cell growth // Cancer Res. - 1993. – Vol.
53.– P. 851–856.
296.Реброва О.Ю. Статистический анализ медицинских данных.
Применение пакета прикладных программ STATISTICA. – М.:
МедиаСфера, 2003. – 312 с.
297. Zweig М., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine // Clinical Chemistry. – 1993. – Vol. 39(8). – P. 561–577.
298.Герасимов А.Н. Медицинская статистика. Учебное пособие. – М.:
ООО «Медицинское информационное агенство», 2007. – 480 с.
299.Turesson C., Jacobsson L.T., Sturfelt G. er al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extraarticular manifestations in rheumatoid arthritis // Ann. Rheum. Dis. – 2007. –
Vol. 66. – P. 59-64.
300.Bas S., Perneger T.V., Seitz M. et al. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors // Rheumotology. – 2002. – Vol. 41. – P. 809-814.
301.Amri M., Sfar I., Ounallah H.S., Dhaouadi T. et al. Anti-CCP antibodies, rheumatoid factors and anti-keratin antibodies: clinical value in established rheumatoid arthritis // Tunis Med. – 2011. – Vol. 89(3). – P. 231-235.
302.Mathsson L., Mullazehi M., Wick M.C. et al. Antibodies against citrullinated vimentin in rheumatoid arthritis higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides // Arthritis Rheum. – 2008. – Vol. 58(1). – P. 36-45.
243
303.Forslind K., Ahlmén M., Eberhardt K. et. al. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP) // Ann. Rheum. Dis. – 2004. – Vol. 63. – P. 1090–1095.
304.Kastbom A., Strandberg G., Lindroos A. et al. Anti-CCP antibody test predicts the disease course during three years in early rheumatoid arthritis (the TIRA project) // Ann. Rheum. Dis. – 2004. – Vol. 63. – P. 1085–1089.
305.Shankar S., Grover R., Handa R. Role of anticyclic citrullinated peptide antibodies in erosive disease in patients with rheumatoid arthritis // Indian J. Med. Res. – 2006. – Vol. 124. – P. 689-696.
306.Mewar D., Coote A., Moore D.J. et al. Independent associations of anticyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis [Электронный ресурс] // Arthritis Res. Ther. –
2006. – Vol. 8. - Режим доступа: http://arthritis-research.com/content/8/4/R128.
307.Agrawal S., Misra R., Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA // Clin. Rheumatol. – 2007.
– Vol. 26. – P. 201–204.
308.Mutlu N., Bicakcigil M., Tasan D. A. et al. Comparative erformance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis // Journal of Rheumatology. – 2009. - Vol. 36. – Vol. 3. – P. 491–500.
309.Coenen D., Verschueren P., Westhovens R. et al. Technical and diagnostic performance of 6 assays for themeasurement of citrullinated protetn/peptide antibodies in the diagnosis of rheumatoid arthritis // Clinical Chemistry. – 2007. - Vol. 53(3). - P. 498–504.
310.Novikov A., Alexandrova E., Karateev D. et al. Diagnostic value of antibodies against a modified citrullinated vimentin, cyclic citrullinated peptide and IgM rheumatoid factor in early rheumatoid arthritis // Annals of the Rheumatic Diseases. – 2007. - Vol. 66(2). – P. 333.
244
311.Sghiri R., Bouajina E., Bargaoui D. et al. Value of antimutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis // Rheumatology International. – 2008. - Vol. 29(1). - P. 59–62.
312.Rantapaa-Dahlqvist S. “Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis // Scandinavian Journal of Rheumatology. – 2005. - Vol. 34(2). – P. 83–96.
313.Combe B., Landewe R., Lukas C. et al. “EULAR recommendations for
themanagement of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) // Annals of the Rheumatic Diseases. – 2007. - Vol. 66(1). - P. 34–45.
314.Salvador G., Gomez A., Vinas O. et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? // Rheumatology. – 2003.
– Vol. 42. – P. 972–975.
315.Mediwake R., Isenberg D.A., Schellekens G.A., et al. Use of anticitrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis // Ann. Rheum. Dis. – 2001. – Vol. 60. – P. 67–68.
316.Zeng X., Ai M., Tian X. et al. Diagnostic value of anticyclic citrullinated peptide antibody in patients with rheumatoid arthritis // J. Rheumatol. – 2003. –
Vol. 30. – P. 1451-1455.
317.Bang H., Luthke K., Gauliard A. et al. Mutadet citrullinated vimentin (MCV) as a candidate autoantigen for diagnosis and monitoring of disease activity in rheumatoid arthritis. Annals of Rheumatic disease. – 2006. - Vol. 65(11). – P. 144.
318.Rodrigues-Mahou M., Lopez-Longo F., Sanchez-Ramon S. et al. Association of Anti–Cyclic Citrullinated Peptide and Anti-Sa/Citrullinated Vimentin Autoantibodies in Rheumatoid Arthritis // Arthritis & Rheumatism (Arthritis Care & Research). – 2006. - Vol. 55. – P. 657–661.
245
319. Vossenaar E.R., Despres N., Lapointe E. et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin // Arthritis Res. Ther. – 2004. – Vol. 6. – P. 142-150.
320.Wagner E., Skoumal M., Bayer P. M. et al. Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis // Rheumatology International. – 2009. - Vol. 29(11). - P. 1315–1321.
321.Liu X., Jia R., Zhao J. et al. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of earlyrheumatoid arthritis // Journal of Rheumatology. – 2009. - Vol. 36(6). – P. 1136–1142.
322.van der Woude D., Ioan-Facsinay A., Schwarte C. et al. Fine specificity of the anti-citrullinated protein antibody response in relationship to the disease course of rheumatoid arthritis // Annals of the Rheumatic Diseases. – 2008. - Vol. 67(2). – P. 75.
323.Ursum J., Nielen M., van Schaardenburg D. et al. Antibodies to mutated citrullinated vimentin and diseaseactivity score in early arthritis: a cohort study [Электронный ресурс] // Arthritis Research and Therapy. – 2008. - Vol. 10(1). –
Режим доступа: http://arthritis-research.com/content/10/1/R12.
324.A. Kinloch, V. Tatzer, R. Wait et al. Identification of citrullinated alphaenolase as a candidate autoantigen in rheumatoid arthritis // Arthritis Research & Therapy. – 2005. - Vol. 7(6). - P. 1421–1429.
325.Zablocki R.W., van der Helm-van Mil A., Huizinga T., Rao S. A Novel Diagnostic Marker for RA, Anti-MCV // Arthritis Rheum. – 2010. – Vol. 62(10).
– P. 660.
326.Vasiliauskiene L., Wiik A., Hoier-Madsen M. Prevalence and clinical significance of anti-keratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis // Ann. Rheum. Dis. – 2001. – Vol. 60. – P. 459-466.
327.Quinn M.A., Gough A.K.S., Green M. J. et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and
246
predict radiological and functional outcome // Rheumatology. -2006. - Vol. 45(4).
– P. 478–480.
328.Dubucquoi S., Solau-Gervais E., Lefranc D. et al. Evaluation of antictrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumaticdiseases // Ann. Rheum. Dis. – 2004. – Vol. 63. – P. 415–419.
329.Girelli F., Foschi F.G., Bedeschi E. et al. Is Anti Cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis? // Eur. Ann. Allergy. Clin. Immunol. – 2004. – Vol. 36(4). – P. 127-130.
330.Zhao J., Liu X., Wang Z. et al. Is it necessary to combine detection of anticitrullinated protein antibodies in the diagnosis of rheumatoid arthritis? // J. Rheumatol. – 2010. – Vol. 37(12). – P. 2462-2465.
331.Song Y.W., Kang E.H. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies // Q.J.M. – 2010. – Vol. 103. – P. 139-146.
332.Meyer O., Labarre C., Dougados M. et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage // Ann. Rheum. Dis. – 2003. – Vol. 62. – P. 120-126.
333.Vallbracht I., Rieber J., Oppermann M. et al. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis // Ann. Rheum. Dis. – 2004. – Vol. 63(9). – P. 1079–1084.
334.Greiner A., Plischke H., Kellner H. et al. Association of anticyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis // Ann. N. Y. Acad. Sci. – 2005. – Vol. 1050. – P. 295-303.
335.Alexiou I., Germenis A., Ziogas A. et. al. Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis [Электронный ресурс] // BMC Musculoskelet. Disord. – 2007. – Vol. 8. –
Режим доступа: http://www.biomedcentral.com/1471-2474/8/37.
247
336.Nyhäll-Wåhlin B.M., Petersson I.F., Nilsson J.A. Et al. High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis // Rheumatology (Oxford) – 2009. - Vol. 48(4). – P. 416-420.
337.Liao H., Wu J., Kuhn E. et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis // Arthr. Rheum. - 2004. – Vol. 50. – P. 3792–3803.
338.Hammer H.B., Odegard S., Fagerhol M.K. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann. Rheum. Dis. – 2007. – Vol. 66. – P. 1093–
1097.
339.Berntzen H.B., Munthe E., Fagerhol M.K. A longitudinal study of the leukocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis. J. Rheumatol. – 1989. – Vol. 16. – P. 1416–1420.
340.Brun J.G., Jonsson R., Haga H.J. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. J. Rheumatol. – 1994. – Vol. 21. – P. 733–737.
341.Hammer H.B., Odegard S., Syversen S.W. et al. Calprotectin (a majorS100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis // Ann. Rheum. Dis. – 2010. – Vol. 69. – P. 150–154.
342.Dougall W.C., Glaccum M., Charrier K. et al. RANK is essential for osteoclast and lymph node development // Genes. Dev. – 1999. – Vol. 13. – P. 2412-2424.
343.Shalhoub V., Faust J., Boyle W.J. et al. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors // J. Cell. Biochem. – 1999. – Vol. 72. – P. 251-261.
344.Kong Y.Y., Feige U., Sarosi I. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand // Nature. – 1999. – Vol. 402. – P. 304-309.
248
345.Romas E., Bakharevski O., Hards D.K. et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis // Arthritis Rheum. – 2000. – Vol. 43. – P. 821-826.
346.Suda T., Takahashi N., Udagawa N. et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families // Endocr. Rev. – 1999. – Vol. 20. – P. 345-357.
347.Hein G.E., Meister M., Oelzner P. sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to nondestructive chronic arthritis // Rheumatol. Int. - 2008. – Vol. 28(8). P. - 765-769.
348.Geusens P.P., Landewe R.B.M., Garnero P. et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthrititis Rheum. – 2006. - Vol. 54(6). - P. 1772–1777.
349.Ellabban A.S., Kamel S.R., Ahmed S.S. Receptor activator of nuclear factor kappa B ligand serum and synovial fluid level. A comparative study between rheumatoid arthritis and osteoarthritis // Rheumatol. Int. – 2012. Vol. 32(6). – P. 1589-1596.
350.Nikolaisen C., Rekvig O.P., Nossent H.C. Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis // Scand. J. Rheumatol. –
2007. – Vol. 36. – P. 97–100.
351.Forslind K., Eberhardt K., Jonsson A. et al. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis // Br. J. Rheumatol. – 1992. – Vol. 31. – P. 593–598.
352.Mansson B., Carey D., Alini M. et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism // J. Clin. Invest. – 1995. –
Vol. 95. – P. 1071–1077.
353. Wollheim F.A., Eberhardt K.B., Johnson U. Et al. HLA DRB1* typing and cartilage oligomeric matrix protein (COMP) as predictors of joint destruction in recent-onset rheumatoid arthritis // Br. J. Rheumatol. – 1997. – Vol. 36. – P. 847– 849.
249
354. Andersson M.L., Svensson B., Petersson I.F. et al. Early increase in serumCOMP is associated with joint damage progression over the first five years in patientswith rheumatoid arthritis [Электронный ресурс] // BMC Musculoskelet. Disord. 2013. Vol. 2(14). – Режим доступа: http://www.biomedcentral.com/1471-2474/14/229.
355.Young-Min S., Cawston T., Marshall N. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers // Arthritis Rheum. – 2007. - Vol. 56(10). - P. 3236–3247.
356.Fex E., Eberhardt K., Saxne T. Tissue-derived acromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet // British Journal of Rheumatology. – 1997. – Vol. 36. P. 1161-1165.
357.Saxne T., Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fl uid and blood // Br. J. Rheumatol. – 1992. – Vol. 31. – P. 583–591.
358.Roux Lombard P., Eberhardt K., Saxne T. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5 year study // Rheumatology. – 2001. – Vol. 40(5). – P. 544-551.
359.Fujikawa K., Kawakami A., Tamai M. High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion // J. Rheumatol. – 2009. – Vol. 36(6). – P. 1126-1129.
360.Soderlin M.K., Kastbom A., Kautiainen H. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity // Scand. J. Rheumatol. – 2004. – Vol.33(3). – P. 185-188.
361.Kawashiri S.Y., Kawakami A., Ueki Y. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with
250
CRP, IgM-RF, MMP-3 and anti-CCPAb // Joint Bone Spine. – 2010. – Vol.
77(5). – P. 418-420.
362.Wisłowska M, Jabłońska B. Serum cartilage oligomeric matrix protein
(COMP) in rheumatoid arthritis and knee osteoarthritis // Clin. Rheumatol. –
2005. – Vol. 24(3). – P. 278-284.
363.Marti C., Neidhart M., Gerber T. Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis. // Z. Rheumatol. - 1999. – Vol. 58(2). – P. 79-87.
364.Hashimoto J. Garnero P. Heijde D. et al. A combination of biochemical markers of cartilage and bone turnover,radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs // Mod. Rheumatol. - 2009. –
Vol. 19. – P. 273-282.
365.Lash G.E., Scaife P.J., Innes B.A. Comparison of three multiplex cytokine analysis systems: Luminex, SearchLight and FAST Quant // J. Immunol. Methods. – 2006. – Vol. 309(1-2). – P. 205-208.
366.Fu Q., Zhu J., Van Eyk J. Comparison of Multiplex Immunoassay Platforms. // Clin. Chem. – 2010. – Vol. 56(2). – P. 314–318.
367.Чечеткин Д. В., Прокопенко Д. В., Макаров А. А. и соавт. Биочипы для медицинской диагностики // Российские нанотехнологии. – 2006. - №
1(1, 2). – С. 13-27.
368.Finkel N.H., Lou X., Wang C. et al. Barcoding the microworld. Anal Chem. 2004. - Vol. 76(19). - P. 352-359.
369.Braeckmans K., De Smedt S.C., Leblans M. et al. Encoding microcarriers: present and future technologies // Nat. Rev. Drug Discov. – 2002. – Vol. 1(6). – P. 447-456.
370.Fortina P., Kricka L.J., Surrey S. et al. Nanobiotechnology: the promise and reality of new approaches to molecular recognition // Trends Biotechnol. –
2005. – Vol. 23(4). – P. 168-173.